Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.

The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, rejecting a proposal issued late last year by the Biden administration. The decision deals a blow,

Under the Biden administration proposal unveiled last November, an estimated 3.4 million Americans on Medicare would be eligible in 2026 for the drugs, which carry a list price of more than $1,000 a month.